Adverse Effects Associated with Second-Generation Antipsychotic Long-Acting Injection Treatment: A Comprehensive Systematic Review

被引:30
作者
Gentile, Salvatore [1 ,2 ]
机构
[1] Mental Hlth Ctr, ASL Salerno, Dept Mental Hlth, I-84013 Salerno, Italy
[2] Univ Naples Federico II, Dept Neurosci, Med Sch Federico 2, I-80138 Naples, Italy
来源
PHARMACOTHERAPY | 2013年 / 33卷 / 10期
关键词
atypical antipsychotic long-acting injections; aripiprazole long-acting injection; olanzapine pamoate; paliperidone palmitate; risperidone long-acting injection; safety; tolerability; CONVENTIONAL DEPOT ANTIPSYCHOTICS; BIPOLAR I DISORDER; INJECTABLE RISPERIDONE; OPEN-LABEL; PALIPERIDONE PALMITATE; DOUBLE-BLIND; SCHIZOAFFECTIVE DISORDER; MAINTENANCE TREATMENT; ORAL ANTIPSYCHOTICS; STABLE PATIENTS;
D O I
10.1002/phar.1313
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
As second-generation antipsychotic long-acting injections (SGA-LAIs) are rapidly replacing depot first-generation antipsychotics as first-line agents in treating schizophrenia spectrum disorders, a systematic assessment of their adverse effects is timely. English-language, peer-reviewed articles reporting original data on the safety and tolerability of SGA-LAIs were identified electronically by searching the MEDLINE, EMBASE, PsycINFO, and DARE databases and the Cochrane Library (January 2001-April 2013). In addition to second-generation (atypical) antipsychotics and long-acting injection (depot) antipsychotics, a separate search was performed for each available drug: aripiprazole LAI, olanzapine pamoate, paliperidone palmitate, and risperidone LAI. Articles were excluded if they were review articles, post hoc analyses, analyses of subsets of patients enrolled in previous trials, single case reports, case series studies, small naturalistic studies (involving less than 50 patients), studies providing no safety data, and studies lasting less than 8weeks. Of 181 articles identified from the search, 140 were excluded; thus, 41 articles met the inclusion criteria. Predictably, the reviewed information revealed that SGA-LAIs have safety profiles consistent with their oral parent formulations. However, they seem to also show unforeseen and worrisome safety signals. Indeed, the routine use of olanzapine-LAI in clinical practice could be limited not only by the well-known risk of postinjection syndrome, whose clinical management remains a matter of concern, but also by the risk of worsening of psychosis. The reviewed information seems to suggest that worsening of psychotic symptoms and depression could also be associated with both risperidone-LAI and paliperidone palmitate. The leading cause of death among patients enrolled in risperidone-LAI studies was suicide. Given the exponential growth in the clinical use of SGA-LAIs, further studies must be urgently performed in order to confirm or exclude the potential safety signals associated with such drugs.
引用
收藏
页码:1087 / 1106
页数:20
相关论文
共 71 条
[1]   Systematic meta-review of depot antipsychotic drugs for people with schizophrenia [J].
Adams, CE ;
Fenton, MKP ;
Quraishi, S ;
David, AS .
BRITISH JOURNAL OF PSYCHIATRY, 2001, 179 :290-299
[2]  
Adams CE, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.cd000307, DOI 10.1002/14651858.CD000307]
[3]   Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases [J].
Alphs, Larry ;
Gopal, Srihari ;
Karcher, Keith ;
Kent, Justine ;
Sliwa, Jennifer Kern ;
Kushner, Stuart ;
Nuamah, Isaac ;
Singh, Jaskaran .
CURRENT DRUG SAFETY, 2011, 6 (01) :43-45
[4]  
[Anonymous], RISP LONG ACT INJ RI
[5]  
Arunpongpaisal Suwanna, 2010, Journal of the Medical Association of Thailand, V93, P343
[6]   A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia [J].
Ascher-Svanum, Haya ;
Zhu, Baojin ;
Faries, Douglas ;
Lacro, Jonathan P. ;
Dolder, Christian R. .
JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (07) :1114-1123
[7]   Antipsychotic long-acting injections: prescribing practice in the UK [J].
Barnes, Thomas R. E. ;
Shingleton-Smith, Amber ;
Paton, Carol .
BRITISH JOURNAL OF PSYCHIATRY, 2009, 195 :S37-S42
[8]   Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study [J].
Brnabic, A. J. M. ;
Kelin, K. ;
Ascher-Svanum, H. ;
Montgomery, W. ;
Kadziola, Z. ;
Karagianis, J. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (09) :945-953
[9]   Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets [J].
Chue, P ;
Eerdekens, M ;
Augustyns, I ;
Lachaux, B ;
Molcan, P ;
Eriksson, L ;
Pretorius, H ;
David, AS .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 (01) :111-117
[10]   Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities [J].
Citrome, Leslie ;
Jaffe, Ari ;
Levine, Jerome .
SCHIZOPHRENIA RESEARCH, 2010, 119 (1-3) :153-159